7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,916.51

+641.44

+0.83%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

GRI Bio, Inc. (GRI)

1.5300 -0.0400 (-2.55%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for GRI

Chart Range Bar

Interval:

In partnership with ChartIQ

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

GRI Bio Featured in

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Grainger H1 Earnings Call Highlights

Grainger H1 Earnings Call Highlights

JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Mobilize your Website

View Site in Mobile | Classic

Share by: